Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus platinum-doublet chemotherapy as neoadjuvant therapy for resectable stage II-IIIA NSCLC
ChiCTR1900023316Phase 4Recruiting
- Sponsor
- Union Hospital
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sintilimab in non-small cell lung cancer (NSCLC), sponsored by Union Hospital. Primary endpoints: Safety, Major pathological response and 1 more. Started May 2019; status: recruiting.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1900023316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023316.